Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology
نویسندگان
چکیده
منابع مشابه
Preparation, Characterization and Evaluation of Olmesartan Medoxomil-β Cyclodextrin Complexes
Olmesartan medoxomil is a poor water soluble drug. There are numerous approaches available and reported in literature to enhance the solubility of poor water soluble drugs among which cyclodextrin complexation is predominant. β-cyclodextrin was used since this possess a special ability to complex with drugs enabling them to increase solubility, reduce bitterness, enhance stability and decrease ...
متن کاملBenicar (olmesartan medoxomil) tablets label
• Nursing mothers: Choose to discontinue nursing or drug (8.3). • In patients with an activated renin-angiotensin system, such as volumeor salt-depletion, renin-angiotensin-aldosterone system (RAAS) blockers such as olmesartan medoxomil can cause excessive hypotension. In susceptible patients, e.g., with renal artery stenosis, RAAS blockers can cause renal failure (5.2, 5.3). • Geriatrics: No o...
متن کاملPreparation and Characterization of Self-Microemulsifying Drug Delivery System of Olmesartan Medoxomil for Bioavailability Improvement
Olmesartan medoxomil (OLM) is an angiotensin II receptor blocker (ARB) antihypertensive agent administered orally that has absolute bioavailability of only 26% due to the poor aqueous solubility (7.75 μg/ml). The aim of the present investigation was to develop a self-microemulsifying drug delivery system (SMEDDS) to enhance the oral absorption of OLM. The solubility of OLM in various oils, surf...
متن کاملOlmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When using combination therapy, antihypertensive agents with complementary mechanisms of action are recommended, for example, an angiotensin receptor blocker (ARB) in combination with hydrochlorothiazide (HCTZ), a beta-blocker + HCTZ, an AC...
متن کاملOlmesartan medoxomil: current status of its use in monotherapy
Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 weeks' treatment with olmesartan medoxomil was significantly more effective than placebo in terms of the response rate, proportion of patients achieving target blood pressure (BP) and mean change from baseline in diastolic (DBP) and systolic blood pressure (SBP). Olmesar...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Saudi Pharmaceutical Journal
سال: 2016
ISSN: 1319-0164
DOI: 10.1016/j.jsps.2015.03.008